Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
509
datasets available to search
ShareScore release 0.9.0
Dataset results
509 results for “Hepatitis C Virus”
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
ClinicalTrials.gov study NCT00006164. IPD Sharing: YES. Countries: 1. Publications: 35.
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
ClinicalTrials.gov study NCT03089944. IPD Sharing: YES. Countries: 19. Publications: 1.
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection
ClinicalTrials.gov study NCT01097395. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
ClinicalTrials.gov study NCT01667731. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
ClinicalTrials.gov study NCT02868242. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
ClinicalTrials.gov study NCT02966795. IPD Sharing: YES. Countries: 9. Publications: 2.
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
ClinicalTrials.gov study NCT02349048. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
ClinicalTrials.gov study NCT03069365. IPD Sharing: UNDECIDED. Countries: 10. Publications: 2.
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
ClinicalTrials.gov study NCT00136318. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
ClinicalTrials.gov study NCT01636778. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
ClinicalTrials.gov study NCT03036852. IPD Sharing: YES. Countries: 6. Publications: 1.
3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
ClinicalTrials.gov study NCT01349465. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
ClinicalTrials.gov study NCT02114177. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Hepatitis C Virus(HCV) Heart and Lung Study
ClinicalTrials.gov study NCT02858180. IPD Sharing: YES. Countries: 1. Publications: 9.
Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data
<p>This upload contains data and all the scripts required to reproduce the results of the artice entitled "Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data".</p> <p><strong>Code is located within Code.zip</strong> . It contains scripts in R and Bash and launchers. Some of the scripts require data files contained within Data.zip.</p> <p><strong>Data is located within Data.zip</strong> , such as the sequences, the inferred phylogeny and the Beast XML file.</p>
Data from: The burden of Hepatitis C virus infection in Punjab, India: a population-based serosurvey
Introduction: Hepatitis C virus (HCV) infection prevalence is believed to be elevated in Punjab, India; however, state-wide prevalence data are not available. An understanding of HCV prevalence, risk factors and genotype distribution can be used to plan control measures in Punjab. Methods: A cross-sectional, state-wide, population-based serosurvey using a multi-stage stratified cluster sampling design was conducted October 2013 to April 2014. Children aged >5 years and adults were eligible to participate. Demographic and risk behavior data were collected, and serologic specimens were obtained and tested for anti-HCV antibody, HCV Ribonucleic acid (RNA) on anti-HCV positive samples, and HCV genotype. Prevalence estimates and adjusted odds ratios for risk factors were calculated from weighted data and stratified by urban/rural residence. Results: 5,543 individuals participated in the study with an overall weighted anti-HCV prevalence of 3.6% (95% Confidence Interval [CI]: 3.0%-4.2%) and chronic infection (HCV Ribonucleic acid test positive) of 2.6% (95% CI: 2.0%-3.1%). Anti-HCV was associated with being male (adjusted odds ratio 1.52; 95% CI: 1.08-2.14), living in a rural area (adjusted odds ratio 2.53; 95% CI: 1.62-3.95) and was most strongly associated with those aged 40-49 (adjusted odds ratio 40-49 vs 19-29-year-olds 3.41; 95% CI: 1.90-6.11). Anti-HCV prevalence increased with each blood transfusion received (adjusted odds ratio 1.36; 95% CI: 1.10-1.68) and decreased with increasing education, (adjusted odds ratio 0.37 for graduate-level vs. primary school/no education; 95% CI: 0.16-0.82). Genotype 3 (58%) was most common among infected individuals. Discussion: The study findings, including the overall prevalence of chronic HCV infection, associated risk factors and demographic characteristics, and genotype distribution can guide prevention and control efforts, including treatment provision. In addition to high-risk populations, efforts targeting rural areas and adults aged >40 would be the most effective for identifying infected individuals.
CD127 as a Novel Potential Marker for Clearance in Chronic Hepatitis C Virus Patients
Open the record for dataset details and reuse information.
New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin
<p><span><b>Background</b>: Several studies have resulted in controversial data about the recurrence or new incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C who were treated with direct-acting antivirals (DAAs). </span></p> <p><span><b>Aim:</b> This observational study aimed to assess the occurrence rate of HCC in patients who developed a sustained virological response (SVR).. </span></p> <p><span><b>Methods</b>: A six-month prospective study was done at the National Hepatology and Tropical Medicine Research Institute [NHTMRI] in Cairo, Egypt on 150 chronic hepatitis C (CHC) patients treated with sofosbuvir and daclatasvir with or without ribavirin. Patients were assigned into two groups according to their laboratory values to either receive sofosbuvir/daclatasvir and ribavirin (S/D/R) or receive only sofosbuvir/daclatasvir (S/D). The main outcome measure was the occurrence of HCC.</span></p> <p><span><b>Results</b>: SVR-12 was 100%. 8.5% of patients developed HCC in the S/D/R group, while 0% in the S/D group.</span></p> <p><span><b>Conclusion:</b> New incidence or recurrence of HCC may occur in CHC genotype 4 cirrhotic patients receiving sofosbuvir/daclatasvir and ribavirin (difficult to treat) although achieving SVR. The cause of HCC development in this study is cirrhosis, not the administered DAAs.</span></p>
"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt
ClinicalTrials.gov study NCT03510637. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
ClinicalTrials.gov study NCT01001754. IPD Sharing: Not stated. Countries: 11. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.